CREATING MOLECULAR DIAGNOSTICS TO ENABLE THERAPEUTIC INTERVENTION

AltheaDx provides a start-to-finish suite of services focused on molecular biomarker discovery, assay development, assay validation and prospective/retrospective clinical trial testing in support of companion diagnostic development and commercialization. At the core of our services is a comprehensive set of gene expression and genotyping analysis capabilities for both pre-clinical and clinical applications utilizing state of the art genomics tools including real-time PCR, microarray technologies and next-generation sequencing. All of our services can be run under non-GLP, full GLP compliance and CLIA. +

SOLUTIONS

+ DISCOVERY SERVICES

+ DIAGNOSTIC DEVELOPMENT SERVICES

+ CLINICAL TRIAL SERVICES


Our mission is to assist our pharmaceutical and biotechnology partners discover and validate biomarkers that can predict drug response and then to provide an efficient seamless commercialization path to bring the tests to market, reducing the time, risk, and cost of therapeutic development.

  • LATEST NEWS

    • November 9 2012 BACKGROUND AND CLINICAL SIGNIFICANCE BRAF is a human gene encoding the protein,+
    • October 10 2012 Markers in Cancer: A Joint Meeting by ASCO, EORTC and NCI, October+

  • LET’S TALK